Hikma Pharmaceuticals (GB:HIK) has released an update.
Hikma Pharmaceuticals faced significant opposition during their 2024 Annual General Meeting regarding the Rule 9 Waiver for a potential share buyback program. Despite over 20% of shareholders voting against the waiver, the company emphasized the importance of maintaining flexibility to return value through buybacks. Hikma continues to engage with shareholders to address concerns and ensure transparency in its financial strategies.
For further insights into GB:HIK stock, check out TipRanks’ Stock Analysis page.
